Navigation Links
EUCODIS Bioscience and Lohmann Animal Health Announce Achievement of Major Development Milestone
Date:2/26/2009

VIENNA, Austria and CUXHAVEN, Germany, February 26 /PRNewswire/ -- EUCODIS Bioscience, a company developing proteins for the chemical industry, and Lohmann Animal Health (LAH), a company developing and marketing products for animal nutrition and animal health, today announced the achievement of a major development milestone in their collaboration agreement relating to the optimization of an undisclosed protein.

EUCODIS Bioscience has completed the development of the prototype protein which is intended to be part of an innovative LAH product. This achievement triggered a milestone payment to EUCODIS Bioscience from LAH. The development project has moved into its final phase, with LAH testing the protein in the field.

"The achievement of this milestone underlines the capacity of EUCODIS Bioscience to develop enzymes and other proteins for different industrial applications", said Rudy Pandjaitan, PhD, CEO EUCODIS Bioscience. "Together with the upcoming launch of our first commercial enzyme, this achievement further fuels our efforts to aggressively expand our current European focus into the US and Asian markets."

"We are pleased to work with a development partner such as EUCODIS Bioscience that combines industrial discipline with a versatile and proven technology", said Dr. Bruno Kaesler, Managing Director of LAH. "Using their protein know-how and development expertise improves the R&D efficiency of LAH and helps us to provide superior products to our customers".

About Lohmann Animal Health

Lohmann Animal Health (LAH) is a leading provider of feed components and vaccines for farm animals, contributing to a safe food supply. Based in Germany, LAH is active in major markets worldwide, with more than 70 percent of its revenues generated from export sales. The Company has more than 500 employees in Germany and the United States as well as in its subsidiaries and sales offices in over 30 countries.

As European market leader LAH offers a wide variety of proven and innovative products in the Feed Additives segment. They range from amino acids and antioxidants to flavors and colorants to probiotics and enzymes. LAH also offers the entire spectrum of vitamins and provitamins, including beta-carotene, as well as specialties such as L-carnitine and botanicals.

For more information, please visit http://www.lah.de

About EUCODIS Bioscience

EUCODIS Bioscience GmbH develops enzymes and other proteins and related biocatalytic processes that enable the chemical, pharmaceutical and other industries to establish critical manufacturing processes and to generate superior products.

Based on its proven proprietary technology and led by an experienced management team, EUCODIS Bioscience provides products and services that help its customers to improve efficiencies and to meet growing environmental requirements.

The Company commercializes its enzyme expertise and its versatile and powerful technology in development projects with industrial partners. Current partners include industry leaders such as GlaxoSmithKline, Henkel, and Lohmann Animal Health.

The Company was founded in 2007, as a demerger of the "white biotech" business unit of Eucodis GmbH, a company founded in 2004. The Company is headquartered in Austria, Europe, with subsidiaries in France and Germany.

    For more information, please visithttp://www.eucodisbioscience.com

    Contact Lohmann Animal Health:
    Dr. Roland Boerner
    Head of Corporate Communications
    Lohmann Animal Health GmbH & Co KG
    Heinz-Lohmann-Strasse 4
    D-27472 Cuxhaven
    Germany
    +49-4721-747-424
    Roland.Boerner@lah.de

    Company contact EUCODIS Bioscience:
    Rudy Pandjaitan, PhD
    CEO EUCODIS Bioscience
    Brunner Strasse 59
    A-1230 Vienna
    AUSTRIA
    +43-1-86634-9241
    office@eucodisbioscience.com

    Media contact EUCODIS Bioscience:
    Frank Butschbacher
    Investor Relations & Communications
   http://www.butschbacher.net
    +43-650-7844940
    office@butschbacher.net



'/>"/>
SOURCE EUCODIS Bioscience
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. EUCODIS Bioscience Appoints Thomas Fischer as Chief Financial Officer
2. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
3. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
4. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
5. Ohio Ranks Best in the Midwest for Venture Capital Investment in Health Care Bioscience Industry
6. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
7. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
8. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
9. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
10. Todd R. Nelson Named Chief Executive Officer of eBioscience, Inc.
11. Magellan Biosciences Names Steven E. Diamond, PhD, Chief Scientific Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... San Diego, CA (PRWEB) , ... June 27, 2016 , ... ... mClinical solutions for clinical trials, announced today the Clinical Reach Virtual Patient ... and their care circle with the physician and clinical trial team. , Using the ...
(Date:6/27/2016)... , June 27, 2016  Liquid Biotech ... announced the funding of a Sponsored Research Agreement ... circulating tumor cells (CTCs) from cancer patients.  The ... in CTC levels correlate with clinical outcomes in ... These data will then be employed to support ...
(Date:6/24/2016)... SAN DIEGO , June 24, 2016 /PRNewswire/ ... that more sensitively detects cancers susceptible to PARP ... individual circulating tumor cells (CTCs). The new test ... of HRD-targeted therapeutics in multiple cancer types. ... therapies targeting DNA damage response pathways, including PARP, ...
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, ... second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with experienced clinical ... eBook by providing practical tips, tools, and strategies for clinical researchers. , “The ...
Breaking Biology Technology:
(Date:3/31/2016)... , March 31, 2016  Genomics firm Nabsys has ... CEO, Barrett Bready , M.D., who returned to ... the original technical leadership team, including Chief Technology Officer, ... Product Development, Steve Nurnberg and Vice President of Software ... the company. Dr. Bready served as CEO ...
(Date:3/23/2016)... , March 23, 2016 ... Interesse erhöhter Sicherheit Gesichts- und Stimmerkennung mit ... Inc. (NASDAQ: MESG ), ein ... dass das Unternehmen mit SpeechPro zusammenarbeitet, um ... der Finanzdienstleistungsbranche, wird die Möglichkeit angeboten, im ...
(Date:3/22/2016)... and SANDY, Utah , ... which operates the highest sample volume laboratory in ... Genomics and UNIConnect, leaders in clinical sequencing informatics and ... launch of a project to establish the informatics infrastructure ... NSO has been contracted by the Ontario ...
Breaking Biology News(10 mins):